Hyphens Pharma International Ltd.

hyphensgroup.com

“Together We Can!” – With strong belief that Asians can contribute to healthcare of this world through passion, hard work and innovation, Hyphens Pharma International Limited, listed on Catalist, SGX-ST, is today Singapore's leading specialty pharmaceutical and consumer healthcare group. Leveraging on our diverse footprint in ASEAN countries, we have a direct presence in five ASEAN countries – Singapore (HQ), Indonesia, Malaysia, the Philippines and Vietnam, and supplemented by a marketing and distribution network covering six other markets – Bangladesh, Brunei, Cambodia, Hong Kong, Myanmar and Oman.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

news image

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More

BUSINESS INSIGHTS

NANOLOGY PUBLISHES REVIEW ARTICLE OF PRECLINICAL AND CLINICAL RESEARCH SUPPORTING LSAM-DTX

NanOlogy | September 21, 2022

news image

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel has been published in Drug Delivery and Translational Research. The review article entitled Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune‑mediated tumoricidal effects: preclinical and cli...

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

VISIOX PHARMA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR GLAUCOMA

Visiox Pharma LLC | December 09, 2022

news image

Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced that it has received notification from the U.S. Food and Drug Administration that the agency has completed its filing review and accepted for filing the New Drug Application for PDP-716 for the treatment of glaucoma. The FDA has assigned a Prescription Drug User ...

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

HOVIONE AND LAXXON MEDICAL ESTABLISH AN AGREEMENT FOR THE CGMP PRODUCTION OF 3D SCREEN PRINTED PHARMACEUTICAL APPLICATIONS

PRNewswire | March 23, 2023

news image

Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon´s expertise in 3D screen printing, based on their SPID®-Technology, with Hovione's product & process development, engineering and manufacturing expertise in pharmaceutical applications. Under the terms of the agreement, Hovione will establish the Laxxon Medical 3D screen printing technology a...

Read More
news image

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More
news image

BUSINESS INSIGHTS

NANOLOGY PUBLISHES REVIEW ARTICLE OF PRECLINICAL AND CLINICAL RESEARCH SUPPORTING LSAM-DTX

NanOlogy | September 21, 2022

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel has been published in Drug Delivery and Translational Research. The review article entitled Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune‑mediated tumoricidal effects: preclinical and cli...

Read More
news image

BUSINESS INSIGHTS, PHARMACY MARKET

VISIOX PHARMA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR GLAUCOMA

Visiox Pharma LLC | December 09, 2022

Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced that it has received notification from the U.S. Food and Drug Administration that the agency has completed its filing review and accepted for filing the New Drug Application for PDP-716 for the treatment of glaucoma. The FDA has assigned a Prescription Drug User ...

Read More
news image

BUSINESS INSIGHTS, PHARMACY MARKET

HOVIONE AND LAXXON MEDICAL ESTABLISH AN AGREEMENT FOR THE CGMP PRODUCTION OF 3D SCREEN PRINTED PHARMACEUTICAL APPLICATIONS

PRNewswire | March 23, 2023

Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon´s expertise in 3D screen printing, based on their SPID®-Technology, with Hovione's product & process development, engineering and manufacturing expertise in pharmaceutical applications. Under the terms of the agreement, Hovione will establish the Laxxon Medical 3D screen printing technology a...

Read More